For research use only. Not for therapeutic Use.
Drug candidate in clinical development for psychiatric disorders with high affinity for h5-HT1A (partial agonist), h5-HT2A (antagonist), hD2L (partial agonist), hα1B (antagonist) and hα2C-adrenergic (antagonist) receptors (Ki values <1 nM). Brexpiprazole also shows substantial affinity (Ki <5 nM) for hD3, h5-HT2B, h5-HT7, hα1A and hα1D adrenergic receptors, and moderate affinity for hH1 (Ki =19 nM).
| Catalog Number | I047608 |
| CAS Number | 2512192-75-3 |
| Molecular Formula | C25H27N3O2S.2HCl |
| Purity | ≥95% |
| Reference | K. Maeda et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350(3):589-604.
K. Maeda et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014 Sep;350(3):605-14.
N. Yoshimi et al. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav. 2014 Sep;124:245-9. |
